Biogen, Eisai unveil new data on lecanemab, but questions linger on ARIA-E; Spatial biology outfit grabs $33M round
Eisai and Biogen have released more data on lecanemab, another anti-Alzheimer’s drug in the partnership that spawned aducanumab. However, questions about the data remain when …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.